Posts tagged Cats

Overland Park, KS (openPR) 2 October 2010

Vets Vétoquinol participants? s symposium on cardiac and renal CVC in Kansas City 29th August hearing to support three Veterinary Internal summary of published research and clinical trials:

The many benefits of using enzyme inhibitors (ACE inhibitors) in dogs and cats with heart disease, kidney disease and high blood pressure;
The main reasons for monitoring systemic hypertension and proteinuria in patients with renal insufficiency and veterinary
The fundamental need to restrict dietary phosphorus in dogs and cats with chronic renal failure. The speakers were

Clarke Atkins, DVM, DACVIM, professor of medicine and cardiology, the College of Veterinary Medicine, North Carolina State University
Gregory F. Grauer, DVM, MS, DACVIM, professor and chairman of Jarvis Small Animal Internal Medicine, College of Veterinary Medicine, Kansas State University
Larry G. Adams, DVM, PhD, DACVIM, Professor of Internal Medicine for Small Animals, School of Veterinary Medicine, Purdue University

patients with heart disease and reduced cardiac output, which is the renin-angiotensin-aldosterone system (RAAS) is activated, which ultimately in addition to cardiovascular and renal damage. Sun mitigating the effects of the renin-angiotensin-aldosterone with drugs such as ACE inhibitors is beneficial for the heart, kidneys and blood vessels in general, “said Dr. Clarke Atkins. However, when ACE inhibitors have been introduced in patients with chronic cardiac veterinarians was the concern that these drugs can themselves contribute to kidney disease. But numerous studies in dogs, cats and humans have been removed, that the myth.

â? ACE inhibitors are not only not nephrotoxic, but in fact the renal function, an advantage? Said Dr. Atkins. â? ACE inhibitors are a cornerstone in the treatment of chronic heart failure. I think all listed in systolic heart failure, they seem to be sure they are saving kidney, particularly with glomerular diseases, they play a role antihypertensive drugs, improving the length and quality of life, and they also benefit from failure.â heart? Dr. Atkins will veterinary are comfortable with ACE inhibitors in patients with heart disease in Phase II and beyond, and to recognize are that ACE inhibitors probably the time proteinuria in patients with renal failure and identifies Finally, given the ACE inhibitor from the time the patient for systemic hypertension is identified displayed.

accepted. â? Most of us donâ? t can feel patients with renal insufficiency with ACE inhibitors, an injury? Says Dr. Gray. He summarized the data showing that more nephrons in association with intraglomerular hypertension and glomerulosclerosis, irreversible damage developed nephrons are replaced by fibrous scar tissue, which lost to a vicious circle. And more nephrons are lost, â? RAAS provides more vasopressors to pay not only tissue remodeling, and the level of the kidney thatâ? S production.â with increased fibrous scar connected? ? Compare Mr. Grey is to conduct a clinical study of two years at KSU CVM in cats, stage 2 or 3 chronic kidney disease, the impact of Rubenal have a care that Vétoquinol kidney rhubarb contains drugs protect the tissue healthy kidney by minimizing the impact of cytokine, benazepril vs. He said that the effectiveness of the data should Rubenal in spring 2011 ACVIM Forum to be provided.

summary of the studies show that the conditions proteinuria and hypertension, resulting from the activation of RAAS, are things that DVM and testing, monitoring, and treatment should be.

let his colleagues in the audience with an important question: Is it simply a marker of proteinuria and hypertension, severe chronic kidney disease is more rapidly progressive, or take one or two mediating progressive renal injury? â? If they can relieve progressive renal damage, then treatments to reduce or normalize blood pressure reduce or mediate proteinuria, renoprotective and improve survival, â? , Added Dr. Gray.

review of the known studies that show the power of a kidney Dieta? Who phosphorus and protein-restricted? Vs has delayed the start of the clinical symptoms of uremia caused trickle, and improved survival in dogs and cats with chronic renal failure. â? Phosphorus limitation is probably the basis of any power failure and it is important, â? Said Dr. Adams. Mr Adams stressed the importance of the treatment of renal secondary hyperparathyroidism, an aspect often neglected in the treatment of chronic kidney disease.

ignore this condition, because this patientsa? Serum phosphorus is often in the reference range. However, Dr. Adams said that veterinarians should serum phosphorus concentration remains in the lower normal range? Less than 5 mg / dl in patients with stage 2 and 3 of renal disease and not more than 6 in patients with stage 4 chronic kidney disease.

To achieve this, Dr. Adams said veterinarians should begin with a renal diet, then add an intestinal phosphate binder when the phosphorus concentration is normal, but not in this lower range of normal. In a 2008 study at the University of Georgia, Epakitin, a dietary supplement made from chitosan Vétoquinol that binds in the gut of phosphate showed a significant reduction in serum phosphorus hormone and parathyroid hormone cats in phase 2 of CKD without within 56 days of increase calcium levels.

intestinal phosphate binders, which can be mixed directly into foods are effective and acceptable, as Epakitin be the most useful and cost-effective in patients with chronic kidney disease, said Dr. Adams.

Vétoquinol USA, in Fort Worth, Texas, is the property of Vétoquinol, an independent laboratory animal drug industry for pets and animal production markets. The family group is dedicated exclusively to animal health, is the ninth largest company in animal health care worldwide. About 80 percent of sales are generated outside

France.
Vétoquinol

business includes research and development, production and marketing of pharmaceuticals and medicine. Vétoquinol is positioned in the treatment field and has expertise in three therapeutic areas: anti-infectives, analgesics and anti-inflammatory, and cardiology / nephrology

.

The Group currently sells its products in over 100 countries in Europe, North America and Asia / Pacific, with branches in 23 countries and a network of 140 distributors. The company has over 1,550 employees worldwide.

For more information: www.vetoquinolusa.com

for more information on heart and kidney function: www.vetoquinolusa.com / News Media / HeartKidneyAccess.pdf

>

clear = “all”
Bulimia Intervention